QuantumCURE Pro™ 8.0 and 8.1: From Docking Tool to Workflow Engine
- mansour ansari

- Mar 20
- 2 min read

I’m happy to share that QuantumCURE Pro™ has now moved into Versions 8.0 and 8.1, and these upgrades represent something much bigger than a few interface improvements.
Version 8.0 marked an important transition: the system became more than a cloud docking interface. It now supports a real research workflow, where compounds can be docked, scored, reviewed, and organized inside a structured environment built for practical drug discovery work.
With the addition of the Golden List, promising compounds can now be filtered, ranked, reviewed, and promoted instead of disappearing into a flat result table. This gives the platform a real triage layer, a place where computational output begins to turn into scientific decision-making.
Version 8.1 pushed the system further by adding the Wet List, a promoted-candidate workspace that serves as the next staging area for deeper analysis. In simple terms, the workflow is now:
Dock → Score → Golden List → Wet List
That may sound simple, but it changes the nature of the system. QuantumCURE Pro™ is no longer just producing docking scores. It is beginning to behave like a small discovery engine.
Version 8.1 also introduced stronger recovery-aware orchestration. Sessions that stall are no longer acceptable in a serious screening system, so I added resilience features that allow the platform to detect stuck jobs, handle timeouts, recover intelligently, and continue processing instead of collapsing an entire batch because of one bad compound.
To validate that reliability, I also added an internal admin QA tool called Acid Test Overnight, designed to intentionally stress the pipeline with good compounds, ugly compounds, invalid inputs, timeout cases, and rescue scenarios. That kind of testing matters, because unattended overnight screening is one of the real promises of this platform.
So to me, Versions 8.0 and 8.1 represent a major shift.
QuantumCURE Pro™ is evolving from a docking interface into a structured drug discovery workflow platform, one that can score compounds, preserve better candidates, promote selected molecules forward, and prepare for future layers like MD, GANN, and SKALA.
There is still more work ahead, but this is real progress, and I’m proud of it.
— Mansour Ansari

Comments